Where to Find CROs Specializing in Peptide Drug Conjugates?

Companies looking for a peptide drug conjugate (PDC) CRO should search beyond conventional peptide synthesis providers. A PDC combines peptide chemistry with linker and payload chemistry, conjugation, purification and specialized analytical characterization. If a program progresses toward clinical development, process scale-up, CMC and GMP manufacturing also become important. [1-5]

The most suitable partners are therefore usually found among specialized peptide CROs, conjugation specialists and integrated peptide CRO/CDMOs with demonstrated experience in complex peptide chemistry and conjugate development. The right partner depends on the project stage and, more importantly, its greatest technical risk.

This guide explains where specialized PDC CRO capabilities are typically found, which technical capabilities matter most, what sponsors should ask potential partners, and when a CRO or CDMO model is more appropriate..

PDC CROs Are Found Across Three Main Partner Types

Specialized PDC capabilities are generally found in three types of organizations:

There is no single category that is automatically best. A company screening multiple early PDC constructs may prioritize rapid parallel synthesis, while a sponsor with a selected candidate may place greater weight on purification, impurity control and manufacturing scalability.

A Peptide Synthesis Provider Is Not Automatically a PDC CRO

Peptide synthesis is essential to most PDC programs, but the peptide may only be an intermediate. Conjugating a linker and payload can change solubility, hydrophobicity, aggregation tendency, chromatographic behavior and stability. Attachment-site changes can also affect target binding, while linker chemistry influences stability and payload release.

A PDC partner therefore needs to understand not only how to make the peptide, but what happens after the peptide becomes a conjugate.

Five Capabilities That Matter Most When Selecting a PDC CRO

1. Complex Peptide Chemistry

Look for evidence beyond routine linear peptide synthesis. Relevant experience may include cyclic and bicyclic peptides, stapled peptides, non-natural amino acids, stereochemical modifications, PEGylation, fluorescent labeling, chelator installation and other site-specific modifications.

2. Conjugation Expertise

The CRO should discuss conjugation as a development problem rather than a one-step reaction. Ask how the team evaluates attachment position, reaction selectivity, linker and payload stability, unreacted starting materials and conjugation-derived impurities.

3. Purification and Analytical Depth

Potential impurities may include peptide deletion or insertion sequences, epimers, oxidation products, unreacted peptide, linker-related species, free payload and conjugation variants. Strong analytical teams help determine where important impurities originate and how the process can control them.

4. Scale-Up Experience

A milligram-scale procedure does not automatically become a manufacturing process. As scale increases, reaction time, mixing, coupling efficiency, cleavage, chromatography loading, solubility and recovery may change. Ask for examples of difficult peptide or conjugate processes moved beyond research quantities.

5. CMC and GMP Development

For candidates with a clinical pathway, assess process optimization, analytical method development and validation, impurity control, stability studies, specifications, quality systems and GMP production. Early discovery need not be GMP, but the chemistry should have a credible route toward controlled manufacturing.

A Practical PDC CRO Evaluation Scorecard

The First Technical Meeting Should Focus on Molecule-Specific Risk

A useful first meeting should focus on the actual molecule rather than a generic capability presentation. Ask the technical team to identify the highest chemistry or manufacturing risk and explain how it would investigate that risk.

Useful questions include:

Specific scientific reasoning is usually more informative than a long equipment list. A capable team may not know every molecule-specific answer immediately, but it should be able to explain how the problem would be investigated.

Red Flags Reveal Gaps Beyond Synthesis Capacity

Common warning signs include:

Another important warning sign is an inability to explain how unexpected solubility, stability or purification problems would be investigated. Troubleshooting ability is often more valuable than nominal synthesis throughput.

CRO and CDMO Need Change with Development Stage

A PDC CRO is generally most relevant for research-oriented activities such as candidate synthesis, peptide modification, conjugation and early analytical characterization. A PDC CDMO becomes increasingly relevant when the program requires process development, scale-up, formal analytical methods, CMC activities and GMP manufacturing.

Many programs ultimately need both. An integrated CRO/CDMO model can reduce technology transfer, but integration should not substitute for technical expertise in the chemistry and development challenges relevant to the molecule.

Development Continuity Reduces Redevelopment Risk

A PDC project can involve separate suppliers for peptide synthesis, linker or payload preparation, conjugation, analytical development and GMP manufacturing. Each transfer creates an interface where failed conditions, unstable intermediates, difficult impurities, solubility limits and purification behavior may be lost or incompletely communicated.

Maintaining continuity between discovery scientists, process chemists, analytical teams and manufacturing groups can reduce redevelopment as a molecule advances.

How ChemExpress Supports Integrated PDC Development

ChemExpress has developed a peptide platform spanning early synthesis, process development, analytical development, CMC and GMP manufacturing.

Platform data report experience across:

Project experience includes linear, cyclic, bicyclic and stapled peptides, PDCs and peptide precursors for radionuclide conjugate programs. Development capabilities extend beyond synthesis into preparative purification, process optimization, impurity research, analytical method development and validation, stability studies, quality control, CMC support and GMP production.

Relevant Project Experience Demonstrates Problem-Solving Depth

Useful project experience should reveal the technical problems a CRO has actually solved. ChemExpress platform materials include PDC-related work and larger-scale cyclic, bicyclic and highly modified peptide programs. One PSMA-targeting radioligand precursor project encountered high raw-material cost, poor solubility during purification and limited stability.

These are the types of issues sponsors should discuss with potential partners. The decisive question is rarely whether a CRO can synthesize the intended structure once; it is whether the organization can develop a reproducible strategy for synthesizing, purifying, characterizing and scaling that molecule.

Conclusion

Finding a CRO specializing in peptide drug conjugates should begin with the molecule rather than with a supplier directory. PDC development sits at the intersection of peptide chemistry, conjugation, purification, analytical science and drug-substance manufacturing.

The right partner is not necessarily the company with the highest peptide synthesis capacity. It is the organization that can address the project's hardest technical risks today while providing a credible development pathway if the molecule succeeds.

Frequently Asked Questions

Q1: Where can I find CROs specializing in peptide drug conjugates?

A: Look among specialized peptide CROs, conjugation providers and integrated peptide CRO/CDMOs. The best fit depends on whether the project requires discovery synthesis, PDC optimization, process development or GMP manufacturing.

Q2: What should I look for in a PDC CRO?

A: Look for demonstrated expertise in complex peptide chemistry, conjugation, purification, analytical characterization and scale-up. For candidates expected to enter clinical development, CMC and GMP capabilities should also be evaluated.

Q3: Is a custom peptide synthesis company enough for a PDC project?

A: Not always. PDC development introduces linker, payload, conjugation, solubility, purification and impurity-control challenges that may extend beyond conventional custom peptide synthesis.

Q4: Should I choose a PDC CRO or a PDC CDMO?

A: Early discovery programs may primarily need a CRO, while development-stage programs increasingly require CDMO capabilities. If the candidate may advance rapidly, a provider with both discovery and later-stage capabilities can reduce technology-transfer risk.

Q5: What is the best way to evaluate a PDC CRO?

A: Ask the technical team to identify the largest risk in the actual molecule and explain how it would investigate it. Specific scientific reasoning and relevant project experience are generally more informative than equipment lists or broad capability claims.

References

1. Armstrong A, Coburn F, Nsereko Y, Al Musaimi O. Peptide-Drug Conjugates: A New Hope for Cancer. Journal of Peptide Science. 2025;31(8):e70040.

2. Fajar M, Maharani R, Supratman U. Linkers for effective peptide-drug conjugates. Bioorganic & Medicinal Chemistry. 2026;133:118510.

3. Jin H, Yang P, Min H, Song J, Qi Y. Peptide-drug conjugates in tumor therapy: Current advances and future perspectives. Cancer Letters. 2026;638:218174.

4. Rizvi SFA, Zhang L, Zhang H, Fang Q. Peptide-Drug Conjugates: Design, Chemistry, and Drug Delivery System as a Novel Cancer Theranostic. ACS Pharmacology & Translational Science. 2024;7(2):309-334.

5. Fu C, Yu L, Miao Y, Liu X, Yu Z, Wei M. Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?. Acta Pharmaceutica Sinica B. 2023;13(2):498-516.

6. International Council for Harmonisation. ICH Q11: Development and Manufacture of Drug Substances. ICH Quality Guidelines. Current official guideline page.